Core Insights - A total of 77 stocks in the Shanghai and Shenzhen markets have experienced net inflows of main funds for five consecutive days or more as of November 5, with Cambricon Technologies (寒武纪-U) leading with 50 days of continuous inflow [1] - The total net inflow of main funds for Cambricon Technologies reached 6.325 billion yuan, followed by Shanghai Pudong Development Bank with a net inflow of 777 million yuan over five days [1] - In terms of the proportion of net inflow to trading volume, *ST Baoying ranks first, with a 47.72% increase over the past eight days [1] Summary by Category Stocks with Continuous Net Inflows - Cambricon Technologies (688256) has seen net inflows for 50 days totaling 6.325 billion yuan, with a price increase of 44.33% [1] - Shanghai Pudong Development Bank (600000) recorded net inflows of 777 million yuan over five days, with a price increase of 0.42% [1] - CITIC Bank (601998) had net inflows of 439 million yuan over six days, with a price increase of 3.85% [1] Notable Performers - *ST Baoying had the highest net inflow ratio, with a significant price increase of 47.72% over the last eight days [1] - Other notable stocks include Jiangsu Bank (600919) with a net inflow of 342 million yuan and a price increase of 5.70%, and Yaxing Anchor Chain (601890) with a net inflow of 331 million yuan and a price increase of 10.16% [1] Additional Stocks with Inflows - Other stocks with notable net inflows include: - China Shenhua (601088) with 314 million yuan and a 3.42% increase [1] - Haotian Co., Ltd. (603759) with 166 million yuan and a 64.35% increase over 11 days [1] - Microelectronic Physiology (688351) with 140 million yuan and a 12.94% increase [1]

Core Insights - DiZhe Pharmaceutical (688192) will present multiple latest research findings on its key lymphoma treatment products, Golixty (generic name: Golixty capsules) and Birelentinib (DZD8586), at the 67th American Society of Hematology (ASH) conference from December 6 to 9 [1] Group 1: Product Developments - The ASH conference will showcase Golixty's exploration and progress in monotherapy and combination therapy strategies for r/r PTCL, first-line treatment, and rare subtypes, highlighting its broad application potential in T-cell lymphoma treatment [1] - Birelentinib is a globally innovative non-covalent dual-target inhibitor of LYN/BTK that can fully penetrate the blood-brain barrier, with the latest data from I/II clinical studies in CLL/SLL patients previously treated with covalent or non-covalent BTK inhibitors and BTK degraders to be presented [1]

证券代码：688192 证券简称：迪哲医药 公告编号：2025-57 迪哲（江苏）医药股份有限公司 自愿披露关于高瑞哲®和 Birelentinib 多项研究 入选第 67 届美国临床血液学会（ASH）大会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 (1) 国际多中心注册临床研究 JACKPOT8 Part B 最新 2 年随访数据：美国单 中心分析显示，接受高瑞哲®治疗获持续缓解，疗效与耐受性与整体研究人群一 致 1 (2) 高瑞哲®作用机制研究提示，高瑞哲®单药可调节 PTCL 免疫微环境，联 合西达本胺可产生抗 PTCL 的协同增效作用 (3) 高瑞哲®回顾性研究显示，其单药或联合治疗方案针对 r/r PTCL 伴噬血 细胞性淋巴组织细胞增多症（HLH）表现出抗 HLH 和抗肿瘤双重活性，且安全 性良好 2. PTCL 一线治疗领域： 迪哲（江苏）医药股份有限公司（以下简称"公司"）将于 12 月 6 日至 9 日在第 67 届美国临床血液学会（American Society of Hematology， ...

Core Viewpoint - The company, DIZHE Pharmaceutical (688192.SH), will present significant research findings on its core lymphoma treatment products at the upcoming 67th American Society of Hematology (ASH) conference from December 6 to 9 [1] Group 1 - The company will showcase two major products: Golixtin (generic name: Golitinib capsules) and birelentinib (DZD8586) [1] - A total of 15 abstracts from the company have been accepted for presentation at the conference, highlighting its extensive pipeline and research potential in the field of hematologic oncology [1]

Core Viewpoint - The company, DIZHE Pharmaceutical (688192), will present multiple research findings on its key lymphoma treatment products, Golitinib (generic name: Golitinib capsules) and Birelentinib (DZD8586), at the 67th American Society of Hematology Annual Meeting from December 6 to 9 [1] Group 1 - The company has 15 abstracts accepted for presentation at the conference, highlighting its extensive pipeline and research potential in the field of hematologic oncology [1]

Core Viewpoint - The company, DIZHE Pharmaceutical (688192.SH), will present multiple research findings on its key lymphoma treatment products at the upcoming 67th American Society of Hematology (ASH) conference from December 6 to 9, showcasing its robust pipeline and research potential in the field of hematologic oncology [1] Group 1 - The company will unveil research results for two core products: Golitiximab (highly regarded as 高瑞哲®) and birelentinib (DZD8586) [1] - A total of 15 abstracts from the company have been accepted for presentation at the ASH conference, highlighting its extensive pipeline in blood cancer treatment [1] - The participation in this prestigious conference reflects the company's commitment to advancing research in hematologic malignancies [1]

Core Viewpoint - The company, DIZHE Pharmaceutical (688192.SH), will present significant research findings on its core lymphoma treatment products, Golixty (generic name: Golitinib capsules) and birelentinib (DZD8586), at the 67th American Society of Hematology (ASH) conference from December 6 to 9 [1] Group 1 - The company has 15 abstracts accepted for presentation at the ASH conference, highlighting its extensive pipeline and research potential in the field of hematologic oncology [1]

Core Insights - The company, DIZHE Pharmaceutical (688192.SH), will present multiple research findings on its core lymphoma treatment products, Golitinib (高瑞哲®) and birelentinib (DZD8586), at the 67th American Society of Hematology (ASH) conference from December 6 to 9 [1] - A total of 15 abstracts from the company have been accepted for the conference, highlighting its extensive pipeline and research potential in the field of hematologic oncology [1]

Group 1 - The core viewpoint of the article is that China Galaxy has given a "recommended" rating to Dize Pharmaceutical (688192.SH) based on significant developments in its product pipeline [1] - Shuwotini has received overseas approval for market launch, and multiple achievements have been selected for the 2025 WCLC [1] - The dual-target BTK has received fast track designation and is set to be showcased at the 2025 ASH [1]

Core Viewpoint - DIZHE Pharmaceuticals, established in 2017 and listed in 2021, focuses on innovative therapies for malignant tumors and has a competitive product pipeline with two products already on the market [1] Business Performance - For Q3 2025, DIZHE Pharmaceuticals reported revenue of 586 million yuan, ranking 73rd in the industry, while the industry leader, Huadong Medicine, reported revenue of 32.664 billion yuan [2] - The net profit for the same period was -583 million yuan, placing the company 109th in the industry, with the top performer, Heng Rui Medicine, achieving a net profit of 5.76 billion yuan [2] Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 51.15%, higher than the industry average of 35.26%, but down from 73.38% year-on-year, indicating reduced debt pressure [3] - The gross profit margin stood at 95.68%, significantly above the industry average of 57.17%, despite a slight decrease from 97.73% in the previous year, reflecting strong profitability [3] Executive Compensation - Chairman and CEO Xiaolin Zhang's compensation for 2024 was 6.0572 million yuan, a decrease of 3.4776 million yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 5.01% to 8,806, with an average holding of 46,500 shares, up 108.97% from the previous period [5] Revenue and Profit Forecast - According to Huatai Securities, DIZHE Pharmaceuticals is expected to achieve nearly 800 million yuan in revenue from its product Shuwotini in 2025, with a domestic peak potential of over 2 billion yuan [6] - Donghai Securities highlighted the company's strong R&D and commercialization capabilities, predicting revenues of 700 million, 1.225 billion, and 2.314 billion yuan for 2025 to 2027 [7]